Cutaneous, oral and genital lichenoid reactions associated with retifanlimab, a new <scp>PD</scp>‐1 inhibitor

Damme, Claire van; Demols, A.; Marmol, Véronique Del

doi:10.1111/jdv.18785

Cited by 4 publications

(1 citation statement)

References 10 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Skin-related symptoms are common during immunotherapy. A clinical diagnosis of immune-related lichen planus has been reported in patients who developed skin, oral, and genital mucosal involvement after the second cycle of retifanlimab ( 26 ). When skin toxicity occurs, thyroid function and creatinine levels need to be monitored more closely because thyroid inflammation and nephrotoxicity are more common in patients presenting with adverse skin reactions ( 27 ).…”

Section: Discussionmentioning

confidence: 99%

Secondary adrenocortical insufficiency after treatment with retifanlimab: a case report

Zhang,

Xiao,

Zhou

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

With advancements in medical oncology, immune checkpoint inhibitors (ICIs) have become the first-line treatment for many malignancies. ICIs play a significant role in improving cancer prognosis, but a series of immune-related adverse events (irAEs), including immune-related endocrine events (irEEs), caused by ICIs have also aroused concerns. Rapid clinical identification of irAEs caused by ICIs is particularly important. We describe a case of secondary adrenocortical insufficiency (AI) after PD-1 treatment in a postoperative patient with endometrial cancer. A 73-year-old female patient developed anorexia, nausea, vomiting, malaise, electrolyte disturbances, ineffective symptomatic treatment, and decreased serum adrenocorticotropin and cortisol levels six months after retifanlimab treatment. The vomiting resolved, and the electrolyte levels were corrected after 3 days of treatment with glucocorticoids (hydrocortisone, intravenous, 200 mg/day). When patients present with gastrointestinal symptoms, such as poor appetite and nausea, not only symptomatic treatment but also a search for the etiology behind the symptoms is needed, especially in immunotherapy patients who should undergo a thorough evaluation of the endocrine system and be alert for adrenocortical insufficiency.

show abstract

Section: Discussionmentioning

confidence: 99%